Bio-Rad Laboratories, Inc. (BIO) Shares Bought by Synovus Financial Corp

Synovus Financial Corp increased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 46.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 899 shares of the medical research company’s stock after acquiring an additional 287 shares during the period. Synovus Financial Corp’s holdings in Bio-Rad Laboratories were worth $209,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Canada Pension Plan Investment Board bought a new stake in Bio-Rad Laboratories during the 2nd quarter worth approximately $113,000. Pacad Investment Ltd. bought a new stake in Bio-Rad Laboratories during the 2nd quarter worth approximately $113,000. Turner Investments LLC bought a new stake in Bio-Rad Laboratories during the 2nd quarter worth approximately $136,000. Flinton Capital Management LLC grew its position in Bio-Rad Laboratories by 17.6% during the 1st quarter. Flinton Capital Management LLC now owns 640 shares of the medical research company’s stock worth $128,000 after acquiring an additional 96 shares during the last quarter. Finally, Capital Analysts LLC bought a new stake in Bio-Rad Laboratories during the 2nd quarter worth approximately $170,000. Institutional investors and hedge funds own 62.85% of the company’s stock.

Bio-Rad Laboratories, Inc. (NYSE BIO) opened at 218.42 on Monday. The company has a market capitalization of $6.47 billion, a price-to-earnings ratio of 431.66 and a beta of 0.93. The firm has a 50-day moving average price of $223.06 and a 200-day moving average price of $216.05. Bio-Rad Laboratories, Inc. has a 12 month low of $154.70 and a 12 month high of $242.79.

COPYRIGHT VIOLATION WARNING: “Bio-Rad Laboratories, Inc. (BIO) Shares Bought by Synovus Financial Corp” was published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/09/11/bio-rad-laboratories-inc-bio-shares-bought-by-synovus-financial-corp.html.

A number of research firms recently commented on BIO. Zacks Investment Research lowered Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Jefferies Group LLC restated a “buy” rating and set a $275.00 price target on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. TheStreet lowered Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Wells Fargo & Company began coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price target on the stock. Finally, BidaskClub upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Bio-Rad Laboratories has a consensus rating of “Buy” and a consensus price target of $228.80.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the business’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the sale, the executive vice president now owns 2,060 shares of the company’s stock, valued at $444,774.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 28.29% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply